News

If the count of working sales reps is rising, who will those reps be able to visit?

$12.8-billion acquisition will bring 1 billion precriptions/year under one PBM's management

Creation of a holding company streamlines future acquisitions; focus is on specialty drug services

National association wins oversight for the valuable top-level domain (TLD), begins approving online pharmacies' use of it

Veeva OpenKey database service will provide a standardized quality level for global healthcare-provider reference data

Office will serve Shanghai and Suzhou life sciences clients

But a majority of dispensers (pharmacies) are not yet preparing for their July 1 deadline

Top 25 medical-benefit drugs showed an 8% increase over prior year

Besides specialty pharmaceutical pricing, the cost of compounded drugs is highlighted

Literature survey from Altarum Institute finds a growing body of evidence of value

IHS, hereafter to be known as ARxIUM, will expand its injectable-compounding business to include oral solids

Medical marijuana and biosimilars are two topics where 'the will of the people' push decisions

A family-owned pharmaceutical manufacturer plots a 21st-century growth plan

AmerisourceBergen-Walgreens Alliance Boots, and H. D. Smith-Legisym are runners-up

More executional capabilities derive from affiliation with parent, inVentiv Health

Company uses online media to promote fill rates by more than 50%

Identity Hub expedites access to regulated content in prescribing and other commercial applications

Collaboration with American College of Cardiology could result in new health-outcomes results

$2-billion acquisition brings a $5-billion/yr PBM to Rite Aid's 4,600 retail stores

Association's annual specialty-distribution study focuses trend in oncology, chronic diseases

The Parenteral Drug Association offers risk management guidance*

2015 spring meeting focuses on meeting transportation bottlenecks

1.5-10% improvement in 'revenue capture' is possible

Reporting by pharma companies on spending on physicians is becoming a non-event

Analysis from Prime Therapeutics points to severe cost hurdles for biosimilars developed and marketed in the US

New design from Emball'Iso triples payload capacity